WithdrawnPhase 2

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Stopped: Trial terminated due to focus of primary therapeutic areas.

United States0Started 2011-02

Plain-language summary

The purpose of this study is to evaluate whether therapy with farletuzumab is effective and safe in the treatment of resectable, non-functioning pituitary adenomas.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males and females \>18 years old * Diagnosis of non-functional pituitary adenoma * Able and willing to undergo surgical resection of the pituitary tumor * Significant medical conditions must be well-controlled and stable for at least 30 days prior to signing the informed consent form Exclusion Criteria: * Presence of clinically significant pituitary apoplexy * Presence of hormone-secreting adenomas * Presence of compressive optic neuropathy due to pituitary tumor * No prior surgical, medical, or radiation therapy in the last 6 months

What they're measuring

Efficacy of farletuzumab in subjects with resectable, non-functioning pituitary macroadenomas as measured by objective response in the tumor size.

Timeframe: Every 3 months

Trial details

NCT IDNCT01203618

SponsorMorphotek

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-06

View on ClinicalTrials.gov More Resectable, Non-functioning Pituitary Adenoma trials